Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma

Abstract

Abstract Purpose To investigate the expression of nuclear receptor subfamily 1 group D member 1 (NR1D1) and nuclear receptor subfamily 2 group E Member 3 (NR2E3) in retinoblastoma (RB) and their correlation with the clinical and pathological features of RB. Methods Immunohistochemical (IHC) assays were performed to detect and evaluate the expression levels of NR1D1 and NR2E3 in paraffin-embedded tissue samples. The relationship between the expression levels and clinicopathological characteristics of RB patients was analyzed using the χ2 test or Fisher exact test. Results A total of 51 RB patients were involved in this research. The expression levels of NR1D1 (P=0.010) and NR2E3 (P=0.007) were significantly lower in RB tumor tissues than in normal retina. The expression levels of NR1D1 and NR2E3 were less positive in RB patients with advanced stages (P=0.007, P=0.015), choroidal infiltration (P=0.003, P=0.029), and optic nerve infiltration (P=0.036, P=0.003). In addition, a low expression level of NR2E3 was associated with high-risk pathology (P=0.025) and necrosis (P=0.035) of RB tissues. Conclusion The expression levels of NR1D1 and NR2E3 were decreased in RB and closely associated with the clinical stage and high invasion of the disease.These findings provide new insights into the mechanism of RB progression and suggest that NR1D1 and NR2E3 could be potential targets for treatment strategies.